jueves, 23 de marzo de 2017

Lionel Messi "juego limpio" con la hepatitis C ?


It’s not everyday that the number one soccer player in the world gets signed as an ambassador of an enterprise—let alone an Egyptian one—but when the initiative is for that big of a cause, he couldn’t decline the offer! Joining Dani Alvis, Lionel Messi is now officially the face of Tour n’ Cure

Tour n’ Cure provides hepatitis C patients, from all over the world, with an effective and affordable treatment package. It is Egypt’s latest initiative in medical tourism—namely offering the opportunity to treat hepatitis C with the most recent, advanced therapies worldwide, with no waiting time. What’s more, their package offers patients the opportunity to take in the beauty of Egypt and visit historic landmarks during the days of the treatment, while enjoying a relaxing stay at a 5-star hotel.



During this one-week program, patients will be introduced to their team of highly qualified hepatology doctors. They will perform all the necessary medical check-ups, laboratory tests and administer the full course of treatment that is most suitable to the patient’s case. 

Tour n’ Cure has partnered with a selection of state of the art hospitals that have been honoured with numerous awards and recognitions by international organizations. These hospitals include the Egyptian Air Force Hospital and Sharm El Sheikh International Hospital.



Tour n’ Cure has collaborated with Pharco Corporation, one of the leading pharmaceutical manufacturers in the Middle East. Pharco produces the treatments, in line with the latest international standards for Good Manufacturing Practice (GMP) of the pharmaceutical industry.





Why is this based in Egypt, you may wonder? Egypt actually has global recognition when it comes to fighting Hepatitis C. ThisEgyptian program gained high global recognition including the WHO which Celebrated World Hepatitis C day in Cairo in 2015. Moreover, Egypt success in fighting Hepatitis C is energized by ambitious presidential program aiming at treating 1 million patients by the end of 2016. For this purpose, Egypt established 50 Hepatitis C management centers across the country aiming to increase them to 100 centers by the end of 2016, including 18 university hospitals.



Ver: 
Pharco Pharmaceuticals Reports Ravidasvir Achieved 100% Cure Rate To Date When Combined With Sofosbuvir For HCV, Non-Cirrhotic, Genotype 4 Patients


So far, over 300,000 patients were cured during the past year, which was made possible by implementing advanced global disease management protocols at highly affordable costs through locally manufactured medications. 

In case you’re uncertain what Hepatitis C is exactly, it is a liver disease caused by the hepatitis C virus: the virus can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness. The hepatitis C virus is a blood borne virus and the most common modes of infection are through unsafe injection practices, inadequate sterilization of medical equipment, and the transfusion of unscreened blood and blood products. 130–150 million people globally have chronic hepatitis C infection. A significant number of those who are chronically infected will develop liver cirrhosis or liver cancer. There is currently no vaccine for hepatitis C, but research in this area is ongoing.(Ver)


Una publicación compartida de Tour n' Cure (@tourncure) el

Publicar un comentario